Russell Frank Company’s PDL BioPharma, Inc. PDLI Stock Holding History

Russell Frank Company’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$8.89M	Buy	2,670,761 +178,980	+7%	+$558K	0.02%	1017
2015 Q4	$8.91M	Sell	2,491,781 -19,726	-0.8%	-$82.6K	0.02%	955
2015 Q3	$12.6M	Buy	2,511,507 +1,083,572	+76%	+$6.21M	0.02%	762
2015 Q2	$9.18M	Sell	1,427,935 -462,352	-24%	-$3.1M	0.01%	1050
2015 Q1	$13.3M	Buy	1,890,287 +134,707	+8%	+$976K	0.02%	757
2014 Q4	$13.5M	Sell	1,755,580 -180,430	-9%	-$1.43M	0.02%	758
2014 Q3	$14.5M	Sell	1,936,010 -207,841	-10%	-$1.93M	0.03%	707
2014 Q2	$20.8M	Buy	2,143,851 +38,402	+2%	+$342K	0.04%	548
2014 Q1	$17.5M	Buy	2,105,449 +52,410	+3%	+$449K	0.03%	610
2013 Q4	$18.7M	Sell	2,053,039 -73,915	-3%	-$623K	0.03%	565
2013 Q3	$17M	Buy	2,126,954 +37,899	+2%	+$305K	0.03%	635
2013 Q2	$16.1M	Buy	+2,089,055	New	+$16.3M	0.03%	619

Other funds holding PDLI

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Frank Company's PDLI Position: Q1 2016 in Review

Russell Frank Company increased its PDL BioPharma, Inc. (PDLI) stake by 7.2% in Q1 2016, buying an estimated $558K and bringing the position to 2,670,761 shares worth $8.89M. The position accounts for 0.02% of the portfolio, ranked #1017.

Russell Frank Company first reported a position in PDLI in Q2 2013 and has held it in 12 quarters since. The position peaked at $20.8M in Q2 2014. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

Russell Frank Company held 2,670,761 shares of PDL BioPharma, Inc. worth $8.89M as of Q1 2016.
Russell Frank Company bought 178,980 PDL BioPharma, Inc. shares in Q1 2016, an estimated $558K.
PDL BioPharma, Inc. made up 0.02% of Russell Frank Company's portfolio in Q1 2016, its #1017 holding.
Russell Frank Company first reported a position in PDL BioPharma, Inc. in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's PDL BioPharma, Inc. position peaked at $20.8M in Q2 2014.
195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.